Myelodysplastic syndromes – therapy progress over the last two decades

Česká verzia

Authors: A. Jonášová
Authors place of work: I. interní klinika – klinika hematologie 1. lékařské fakulty UK a VFN Praha, přednosta prof. MU Dr. Marek Trněný, CSc.
Published in the journal: Vnitř Lék 2013; 59(7): 635-640
Category:

Summary

Myelodysplastic syndrome is one of the most common hematology diseases in the age over the 60. Until recently the therapy of this disease was frustrating and often based only on supportive care. The last decade witnessed the emergence of promising drugs that represent a major breakthrough in the therapy and interest of decoding of the pathogenesis of this disease. In our work we summarize the evolution of MDS therapy with accent on the new drugs contribution.

Key words:
myelodysplastic syndromes – classification – prognosis – therapy

Zdroje

1. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189– 199.

2. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting‑ Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835– 3849.

3. Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079– 2088. Erratum Blood 1998; 91: 1100.

4. Greenberg PL, Tuechler H, Schanz J et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454– 2465.

5. Schanz J, Tüchler H, Solé F et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012; 30: 820– 829.

6. Armand P, Kim HT, Aleya EP et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586– 4588.

7. Leitch HA, Wong D, Leger C et al. Improved leukemia‑free and overall survival in patients with myelodysplastic syndrome receiving iron chelation therapy: a subgroup analysis. Blood 2007; 110: abstract 1469.

8. Rose C, Brechignac S, Fenaux P et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM. Blood 2007; 110: Abstract 249.

9. Park S, Grabar S, Kelaidi C et al. GFM group (Groupe Francophone des Myélodysplasies). Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G‑CSF: the GFM experience. Blood 2008; 111: 574– 582.

10. Hellström‑ Lindberg E, Gulbrandsen N, Lindberg G et al. Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‑ stimulating factor: significant effects on quality of life. Br J Haematol 2003; 120: 1037– 1046.

11. Thompson JA, Gilliland DG, Prchal JT et al. Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony‑ stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/ EPO MDS Study Group. Blood 2000; 95: 1175– 1179.

12. Jonasova A, Neuwirtova R, Cermak J et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998; 100: 304– 309.

13. Killick SB, Mufti G, Cavenagh JD et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with ‘low‑ risk’ myelodysplasia. Br J Haematol 2003; 120: 679– 684.

14. Shimamoto T, Tohyama K, Okamoto T et al. Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. Leuk Res 2003; 27: 783– 788.

15. Molldrem JJ, Jiang YZ, Barrett AJ et al. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte‑ mediated inhibition of CFU‑ GM and alterations in T‑ cell receptor Vbeta profiles. Br J Haematol 1998; 102: 1314– 1322.

16. Sloand EM, Mainwaring L, Barrett AJ et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005; 106: 841– 851.

17. Barrett J, Sloand E, Young N. Determining which patients with myelodysplastic syndrome will respond to immunosuppressive treatment. Haematologica 2006; 91: 583– 584.

18. Lee SE, Kim YJ, Yahng SA et al. Survival benefits from reduced‑ intensity conditioning in allogeneic stem cell transplantation for young lower‑ risk MDS patients without significant comorbidities. Eur J Haematol 2011; 87: 510– 520.

19. Luger SM, Ringdén O, Zhang MJ et al. Similar outcomes using myeloablative vs reduced‑ intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 2012; 47: 203– 211.

20. Lee SE, Lim J, Yahng SA et al. Reduced‑ intensity conditioning regimen combined with low‑dose total body irradiation in the treatment of myelodysplastic syndrome. Acta Haematol 2011; 126: 21– 29.

21. Jabbour E, Mathisen MS, Garcia‑ Manero Get al. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case‑ control study. Am J Hematol 2013; 88: 198– 200.

22. Raza A, Meyer P, Dutt D et al. Thalidomide produces transfusion independence in long‑standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001; 98: 958– 965.

23. List A, Dewald G, Raza A et al. Myelodysplastic Syndrome‑ 003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456– 1465.

24. Fenaux P, Giagounidis A, Selleslag D et al. MDS‑ 004 Lenalidomide del5q Study Group. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion‑ dependent patients with Low‑ / Intermediate‑ 1- risk myelodysplastic syndromes with del5q. Blood 2011; 118: 3765– 3776.

25. Jädersten M, Saft L, Mufti GJ et al. TP53 mutations in low‑ risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 2011; 29: 1971– 1979.

26. Raza A, Reeves JA, List AF et al. Phase 2 study of lenalidomide in transfusion‑ dependent, low‑ risk, and intermediate‑ 1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008; 111: 86– 93.

27. Hofmann WK, Takeuchi S, Takeuchi N et al. Comparative analysis of hypermethylation of cell cycle control and DNA‑ mismatch repair genes in low‑ density and CD34+ bone marrow cells from patients with myelodysplastic syndrome. Leuk Res 2006; 30: 1347– 1353.

28. Christiansen DH, Andersen MK, Pedersen‑ Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy‑related myelodysplasia and acute myeloid leukemia. Leukemia 2003; 17: 1813– 1819.

29. Curik N, Burda P, Vargova K et al. 5- azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity. Leukemia 2012; 26: 1804– 1811.

30. Shin DY, Park YS, Yang K et al. Decitabine, a DNA methyltransferase inhibitor, induces apoptosis in human leukemia cells through intracellular reactive oxygen species generation. Int J Oncol 2012; 41: 910– 918.

31. Silverman LR, Demakos EP, Peterson BL et al.Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429– 2440.

32. Fenaux P, Mufti GJ, Hellstrom‑ Lindberg E et al. International Vidaza High‑Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher‑ risk myelodysplastic syndromes: a randomised, open‑ label, phase III study. Lancet Oncol 2009; 10: 223– 232.

33. Itzykson R, Thépot S, Quesnel B et al. Groupe Francophone des Myelodysplasies (GFM). Prognostic factors for response and overall survival in 282 patients with higher‑ risk myelodysplastic syndromes treated with azacitidine. Blood 2011; 117: 403– 411.

34. Grövdal M, Khan R, Aggerholm A et al. Maintenance treatment with azacitidine for patients with high‑risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after intensive chemotherapy. Br J Haematol 2010; 150: 293– 302.

35. Damaj G, Duhamel A, Robin M et al. Impact of azacitidine before allogeneic stem‑ cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie‑ Cellulaire and the Groupe‑ Francophone des Myelodysplasies. J Clin Oncol 2012; 30: 4533– 4540.

36. Silverman LR, Fenaux P, Mufti GJ et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‑ risk myelodysplastic syndromes. Cancer 2011; 117: 2697– 2702.